Semaglutide: A Potential New Ally Against Dementia
Semaglutide, the main ingredient found in well-known weight loss medications like Ozempic and Wegovy, is being studied for another possible benefit: brain health. Recent research indicates a connection between the use of semaglutide and a lowered risk of dementia for individuals living with type 2 diabetes.
A study from scientists at Case Western Reserve University, published in the Journal of Alzheimer’s Disease, reveals that diabetes patients using semaglutide face a significantly reduced risk of dementia compared to those on other diabetes treatments. This intriguing finding, the researchers suggest, calls for further investigation, including clinical trials.
Initially, GLP-1 drugs were designed to help manage blood sugar levels in those with type 2 diabetes. However, newer GLP-1 medications like semaglutide have been found to be much more effective for weight loss than just diet and exercise alone. Ongoing studies have shown that these drugs potentially offer even broader health benefits. Researcher Rong Xu and her colleagues are keen to explore these additional advantages. In fact, past studies hinted that semaglutide might help reduce cravings for substances like nicotine or opioids.
While there’s currently no cure for dementia, Xu highlights that up to half of all cases could be preventable. There are several modifiable risk factors linked to dementia risk, including conditions like obesity and type 2 diabetes—issues that GLP-1 medications like semaglutide can help address. Additionally, these drugs appear to have anti-inflammatory properties, which also contribute to lowering dementia risk.
This context suggests that “semaglutide has emerged as a promising candidate” for a preventative measure against dementia, Xu expressed in a conversation. The research team previously found a relationship between semaglutide and a decreased risk of Alzheimer’s disease, the most prevalent type of dementia. To expand their investigation, they evaluated medical records from approximately 1.7 million type 2 diabetes patients.
Over a period of three years, it was observed that individuals on semaglutide had a significantly lower risk—around 40% to 50%—of developing any kind of Alzheimer’s-related dementia compared to those using other diabetes medications like insulin or metformin. This trend was consistent across various demographics, including different age groups and those with or without obesity. Yet, it’s important to note that the reduced risk linked to semaglutide specifically showed up with vascular dementia, the second-most common type, and not with Lewy body dementia or frontotemporal dementia.
They pointed out, “As we and others have previously shown benefit for semaglutide and other GLP-1 receptor agonists in Alzheimer’s disease, our findings support the GLP-1 receptor as a target for dementia prevention,” in their paper.
Despite these promising results, the findings are not conclusive and only indicate a correlation between semaglutide and lower dementia risk. There’s a growing body of encouraging evidence, though, which suggests that clinical trials are warranted to determine any causal links. Currently, Novo Nordisk, the company behind Ozempic and Wegovy, is conducting two significant trials to test semaglutide for Alzheimer’s, both expected to conclude soon. Xu and her colleagues also plan to investigate whether newer, potentially more effective GLP-1 drugs like tirzepatide can provide an even greater safeguard against dementia.
